Stop me if you’ve heard this one: AstraZeneca is having vaccine issues

Remember when I said “we’ll see if anything else happens” in last week’s article on AstraZeneca’s issues? Well, I accept full responsibility for manifesting the chaos that happened earlier this week and I promise I won’t tempt fate again this time around. If you’re confused, as I certainly was, here’s just what the hell happened.

On Monday, AstraZeneca released results from their Phase 3 trials in the United States, and they looked good: 79% efficacy against symptomatic disease, 100% efficacy against hospitalizations and deaths. This was certainly a welcome result for the company which is continuing to grapple with fallout from rare cases of blood clots that have been reported in some people after they got the vaccine, and gears started to turn to get EUA approval in the United States. (Even though, again, the U.S. just promised most of their supply to Canada and Mexico. Everyone wants FDA clout, I guess.)

But on Tuesday, officials started to question the results. The results released on Monday had looked better than more recent results released elsewhere, one of which showed an overall efficacy of around 60%. Also, as Dr. Eric Topol pointed out, the data were fairly incomplete:

Independent reviewers from the data and safety monitoring board sent “a harsh note” to AstraZeneca, according to Anthony Fauci, and sure enough, it soon became clear that AstraZeneca had released outdated (better) numbers instead of the real results from the trial, obfuscating how efficacious the vaccine actually was in the U.S. trial. 

After all this, on Wednesday morning, AstraZeneca released the updated overall efficacy number: 76%. All that drama over docking three percentage points. (Though they did also complete the dataset, thus satisfying Dr. Topol and saving them more of his very pointed tweets. Thank you Dr. Topol.) 

Dr. Ashish Jha sums it up pretty well:

But Roxanne Khamsi sums it up even better:

We’ll see if anything el—nope, I promised I wouldn’t.

Related posts

  • Sources and updates, May 8
    Sources and updates for the week of May 8 include booster shots, vaccine attitudes, wastewater data, and source diversity.
  • The US still doesn’t have the data we need to make informed decisions on booster shots
    Last fall, I wrote that the U.S. did not have the data we needed to make informed decisions about booster shots. Several months later, we still don’t have the data we need, as questions about a potential BA.2 wave and other future variants abound. Discussions at a recent FDA advisory committee meeting made these data gaps clear.
  • Sources and updates, March 13
    Sources and updates for the week of March 13 include vaccine data annotations, free rapid tests, a combination of Delta and Omicron, and more.
  • Pandemic preparedness: Improving our data surveillance and communication
    What has the U.S. learned from the last two years, and what lessons can we take forward for future COVID-19 surges and other infectious disease outbreaks? The Biden administration has released a new pandemic preparedness plan that addresses these questions.

One thought on “Stop me if you’ve heard this one: AstraZeneca is having vaccine issues

Leave a Reply